Pharmaceutical Business review

GSK migraine drug gets UK OTC approval

This move represents the first triptan that can be given without a prescription in the UK and highlights the government's commitment to expand the range of medicines available for 'self-medication.'

The approval for over-the-counter (OTC) sale of this drug is designed to encourage patients to take control of their own healthcare by accessing treatment straight away, while also alleviating pressure on the National Health Service (NHS) by cutting out the need for patients to consult their doctor.

“As triptans should be taken as early as possible in a migraine attack, the pharmacy availability of these important medicines will be beneficial to patients who suffer from migraines, especially those who have infrequent attacks and may not always have prescription medicines to hand,” said Professor Kent Woods, chief executive of the Medicines and Healthcare products Regulatory Agency (MHRA).